Shares of Fibrocell Science Inc. (NASDAQ:FCSC) climbed 42.7% to $2.54 Monday on news that Castle Creek Pharmaceuticals LLC has agreed to support the development and commercialization of FCX-007, Fibrocell's lead gene therapy candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).